Table 7.
The approved polymeric nanomedicines for the cancer therapy.
| Drugs Used | Polymers | Manufacturer | Cancers | Approval Status |
|---|---|---|---|---|
| Abraxane | Paclitaxel in combination with gemcitabine & albumin-bound Paclitaxel nanospheres | Astrazeneca Celgene & Abraxis Bioscience | Metastatic pancreatic cancer | Approved in September 2013 |
| Aroplatin | Liposomes | Antigenics, Inc. | Colorectal cancer | In clinical phase I/II |
| Atragen | Liposomes | AronexPharmaceuticals | Promyelocyticleukemia | In clinical phase II |
| Aurimmune (CYT-6091) | TNF-α | Cytimmune Sciences | Neck & head cancers | In clinical phase II |
| Cisplatin | PEG-b-poly(L-glutamic acid) | Nanocarrier, Co., Japan | Pancreatic cancer | In clinical trial phase II |
| Doxil (Caelyx) | Pegylated | Orthobiotech, Schering-Plough | Breast & ovarian cancers | Approved in 1995 |
| Doxorubicin | Liposomes | - | Ovary cancer | In clinical trial, Jan., 2008, Russia |
| Doxorubicin | PEG-b-poly(α,β-aspartic acid) | Nippon Kayaku, Co., Japan | Solid tumors | In clinical trial phase II |
| DepoCyt | Liposomes | Skye Pharma, Enzon | Lymphomatous meningitis | Approved in 1999 |
| DaunoXome | Liposomes | Gilead Science | HIV-related Kaposi sarcoma | Approved in 1996 |
| Epirubicin | PEG-b-poly(aspartate-hydrazone) | Nippon Kayaku, Co., Japan | Solid tumors | In clinical trial phase I |
| Genexol-PM | Polymeric micelle | Samyang | Lung & breast cancers | Marketed in Europe, Korea |
| LEP-ETU | Liposomes | Neopharma | Breast, lung & ovarian cancers | In clinical phase I/II |
| Lipoplatin | Liposomes | Regulon | Head, neck & pancreatic cancers | In clinical phase III |
| Myocet | Liposomes | Elan Pharmaceuticals/Sopherion Therapeutics | Breast cancer | Approved in 2000, Europe and Canada |
| Narekt-102 | PEGylated liposome | Nektar Therapeutics | Colorectal & breast cancers | In clinical Phase 3 |
| Onco-TCS | Liposomes | Inex | Non-Hodgkin Lymphoma | In clinical phase I/II |
| OSI-211 | Liposomes | OSI | Ovarian & lung cancers | In clinical phase II |
| Oncaspar | PEGasparaginase | Enzon | Lymphocytic Leukemia | Approved in 1994 |
| Ontak | Diphtheria toxin and | Seragen, Inc. | Cutaneous T-cell | Approved 1999 |
| Oxoplatin | PEG-b-poly(L-glutamic acid) | Nippon Kayaku, Co., Japan | Solid tumors | In clinical trial phase I |
| Paclical | Paclitaxel micelles | Oasmia Pharmaceutical AB | Ovarian cancer | Phase III |
| Paclitaxel | Micelles | - | Breast cancer | In clinical trial, 2009, South Korea |
| Paclitaxel | PEG-b-poly(α,β-aspartic acid) PEG–poly(D,L-lactide) | Nippon Kayaku, Co., Japan | Bresat & gastric cancers | In clinical trial phase III |
| SPI-77 | Stealth Liposomal Cisplatin | Alza | Neck, lung & head cancers | In clinical Phase III |
| ThermoDox | Doxorubicin | Celsion Corporation | Hepatocellular carcinoma | In clinical phase III |